Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.
Earnings per share decreased 16.83% year over year to $0.84, which beat the estimate of $0.57.
Revenue of $46,020,000 lower by 7.56% from the same period last year, which missed the estimate of $51,100,000.
Earnings guidance hasn't been issued by the company for now.
Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: May 11, 2020
Time: 08:02 PM ET
Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2Fhome%2Fdefault.aspx&eventid=2323967&sessionid=1&key=EDEC468D718914C24824955A2CD88AB4®Tag=&sourcepage=register
Company's 52-week high was at $64.94
Company's 52-week low was at $33.80
Price action over last quarter: Up 25.07%
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.